Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment save search
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
MYNZ | $0.9 -3.35% -3.47% 52K
|
|
| O: 3.0%
H: 6.8%
C: 0.0%
cancer treatment
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
Published: 2024-03-19 (Crawled : 11:00) - prnewswire.com
TVTX | $5.805 -3.09% -3.19% 970K
|
Health Technology
|
| O: -0.7%
H: 5.47%
C: 4.91%
ferinject health anemia approved treatment canada heart
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 0.84%
H: 5.95%
C: 5.09%
treatment trial therapeutics solriamfetol
Global Neutropenia Market Poised to Reach USD 5.86 Billion by 2028, Amid Rising Cancer Incidence and Advancements in Treatment Options
Published: 2024-03-18 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
BAX | $39.65 0.33% 0.0% 2.3M
|
Health Technology
|
| O: 0.02%
H: 1.03%
C: 0.96%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.11%
H: 0.59%
C: 0.1%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: -0.48%
H: 0.31%
C: 0.13%
reach cancer treatment global market
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Published: 2024-03-18 (Crawled : 13:00) - globenewswire.com
SCLX | $0.8942 -23.57% -30.84% 2.8M
|
|
| O: -0.73%
H: 3.31%
C: 0.74%
elyxyb drug patent company health approval review treatment canada migraine submission
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Published: 2024-03-18 (Crawled : 12:30) - prnewswire.com
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
|
| O: -2.23%
H: 11.11%
C: 0.03%
fda t-cell resubmission treatment pharmaceuticals
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Published: 2024-03-18 (Crawled : 12:30) - globenewswire.com
DERM | $3.54 -8.29% -9.04% 190K
|
|
| O: 2.94%
H: 14.57%
C: 6.86%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 3.36%
H: 0.5%
C: -4.0%
dfd-29 fda drug corporation treatment medical application
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
NTLA | $21.3 -0.93% -0.94% 1.1M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: -2.42%
ntla-2001 first treatment therapeutics study
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
Published: 2024-03-18 (Crawled : 12:00) - biospace.com/
KALV | $11.53 -1.03% -1.04% 410K
|
Health Technology
|
| O: -0.08%
H: 3.61%
C: 0.59%
conference treatment pharmaceuticals
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2024-03-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: -0.27%
H: 4.91%
C: -2.9%
carvykti fda treatment
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Published: 2024-03-15 (Crawled : 20:00) - globenewswire.com
OPTN | $0.9293 -8.89% -9.76% 550K
|
Health Services
| Email alert
Add to watchlist
fda first xhance approved treatment
U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
Published: 2024-03-15 (Crawled : 19:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
carvykti fda treatment
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Published: 2024-03-15 (Crawled : 13:00) - prnewswire.com
GLMD | $0.3669 -0.41% -0.41% 27K
|
Health Technology
|
| O: 17.48%
H: 0.0%
C: -25.59%
mgl-3196 patent liver treatment fibrosis grant aramchol nash
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
Published: 2024-03-15 (Crawled : 13:00) - globenewswire.com
ONCT | News | $8.79 -1.79% -1.82% 2.8K
|
Health Technology
|
| O: -4.32%
H: 8.26%
C: 7.19%
cancer treatment key
Water Treatment Equipment Market size in Power Industry to grow by USD 1.34 billion from 2022 to 2027, Increasing power demand to drive the growth, Technavio
Published: 2024-03-15 (Crawled : 08:00) - prnewswire.com
XYL | $127.16 0.75% 0.0% 1.1M
|
Producer Manufacturing
|
| O: -0.91%
H: 1.14%
C: 0.37%
ECL | $219.21 -0.02% 0.0% 920K
|
Process Industries
|
| O: -0.98%
H: 2.03%
C: 1.83%
water treatment market
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
MDGL | $222.18 -2.7% -2.8% 270K
|
Health Technology
|
| O: 20.66%
H: 2.07%
C: -8.01%
fda liver approval treatment fibrosis pharmaceuticals advanced
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
MIRM | $23.6 -1.05% -1.06% 400K
|
Health Technology
|
| O: 1.49%
H: 2.98%
C: -0.43%
fda pruritus approval treatment livmarli
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Published: 2024-03-13 (Crawled : 20:00) - prnewswire.com
PSTX | News | $2.005 -1.72% -1.75% 520K
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: -4.14%
fda drug granted treatment designation therapeutics
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
Published: 2024-03-13 (Crawled : 13:00) - globenewswire.com
FEMY | News | $1.305 0.39% 0.38% 190K
|
Manufacturing
|
| O: -5.76%
H: 12.78%
C: 0.56%
treatment
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
Published: 2024-03-13 (Crawled : 12:30) - globenewswire.com
PXMD | $0.7784 -2.69% -2.76% 710K
|
Health Technology
|
| O: 0.0%
H: 52.17%
C: -13.03%
company presentation
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.